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Abstract
Dietary strategies for alleviating health complications associated with type 2 diabetes (T2D) are being pursued as alternatives to pharmaceutical interven-
tions. Berries such as bilberries (Vaccinium myrtillus L.) that are rich in polyphenols may inﬂuence carbohydrate digestion and absorption and thus post-
prandial glycaemia. In addition, berries have been reported to alter incretins as well as to have antioxidant and anti-inﬂammatory properties that may
also affect postprandial glycaemia. The present study investigated the acute effect of a standardised bilberry extract on glucose metabolism in T2D.
Male volunteers with T2D (n 8; BMI 30 (SD 4) kg/m2) controlling their diabetes by diet and lifestyle alone were given a single oral capsule of either
0·47 g standardised bilberry extract (36 % (w/w) anthocyanins) which equates to about 50 g of fresh bilberries or placebo followed by a polysaccharide
drink (equivalent to 75 g glucose) in a double-blinded cross-over intervention with a 2-week washout period. The ingestion of the bilberry extract resulted in
a signiﬁcant decrease in the incremental AUC for both glucose (P = 0·003) and insulin (P= 0·03) compared with the placebo. There was no change in the
gut (glucagon-like peptide-1, gastric inhibitory polypeptide), pancreatic (glucagon, amylin) or anti-inﬂammatory (monocyte chemotactic protein-1) peptides.
In addition there was no change in the antioxidant (Trolox equivalent antioxidant capacity, ferric-reducing ability of plasma) responses measured between
the volunteers receiving the bilberry extract and the placebo. In conclusion the present study demonstrates for the ﬁrst time that the ingestion of a con-
centrated bilberry extract reduces postprandial glycaemia and insulin in volunteers with T2D. The most likely mechanism for the lower glycaemic response
involves reduced rates of carbohydrate digestion and/or absorption.
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Dietary strategies for alleviating health complications, such as
premature vascular disease, associated with type 2 diabetes
(T2D) and obesity are actively being pursued as alternatives
to pharmaceutical interventions(1). The genus Vaccinium (for
example, blueberry, bilberry, cranberry) has been used
traditionally as a source of folk remedies for established dia-
betic symptoms.
Berries from this genus are rich in anthocyanins, polyphe-
nols recognised for their ability to provide and activate cellular
antioxidant protection and inhibit inﬂammatory gene
Abbreviations: AUCi, incremental AUC; FRAP, ferric-reducing ability of plasma; GIP, gastric inhibitory polypeptide; GLP-1, glucagon-like peptide-1; MCP-1, monocyte
chemotactic protein-1; OGTT, oral glucose tolerance test; T2D, type 2 diabetes; TEAC, Trolox equivalent antioxidant capacity.
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expression(2–4), activities that may contribute to the efﬁcacy of
the Vaccinium genus as ameliorators for T2D. Consumption of
a freeze-dried blueberry beverage for an 8-week period, for
example, decreased plasma concentrations of the cardiovascu-
lar risk factors oxidised LDL, malondialdehyde and hydroxy-
nonenal. In another trial, bioactives from blueberries
improved insulin sensitivity in obese insulin-resistant men
and women(5,6). In both these studies the investigators
reported no change in inﬂammatory markers following sup-
plementation although bilberry juice was shown to modulate
plasma markers of inﬂammation C-reactive protein and IL-6
in subjects with increased risk of CVD(7). These beneﬁcial
responses from human studies are supported by data that
demonstrate long-term beneﬁcial effects of anthocyanins
from mouse models of obesity and diabetes(8–12).
There are also a number of studies in vitro and in vivo that
suggest that polyphenols inﬂuence carbohydrate digestion and
absorption, resulting in improved postprandial glycaemia in
the short term. Polyphenols inhibit intestinal α-glucosidase
activity(13–17) and glucose transport(13,15,18–21) in vitro. In associ-
ation with this, polyphenols administered to rodents suppress
the elevation of blood glucose concentration after oral admin-
istration of mono- and di-saccharides(13–17,19,22). In human
subjects, several studies have examined the effect of polyphe-
nols on the postprandial glycaemic response(23). In one study,
a test meal of mixed berry purée with sucrose showed a
lower plasma glucose concentration after 15–30 min compared
with a control matched for sugars(24).
Overall, evidence suggests that consuming edible berries,
particularly from the genus Vaccinium, that have high concen-
trations of anthocyanins could provide a supplementary inter-
vention to improve glycaemia in subjects with T2D or
impaired glucose tolerance. The object of the present study
was to investigate whether a single supplementation with a
standardised (36 % (w/w) anthocyanins) concentrated bilberry
extract could alter glucose metabolism in overweight/obese
volunteers with impaired glucose intolerance or T2D com-
pared with a control capsule matched for sugars and to explore
the possible mechanisms of action.
Methods
Subjects
Male volunteer subjects (n 8; BMI 30 (SD 4) kg/m2; aged 62
(SD 5) years) with T2D controlled by diet and lifestyle alone
or with impaired glucose tolerance (Table 1) were recruited
from the Aberdeen area of the UK. Subjects were only
included if they were not on any special religious or prescribed
diet and had a stable weight. Medical exclusion criteria
included chronic illnesses, such as thromboembolic or coagu-
lation problems, thyroid disease, renal or hepatic disease,
severe gastrointestinal disorders, pulmonary disease (for
example, chronic bronchitis, chronic obstructive pulmonary
disease), alcohol or any other substance abuse, eating disorders
or psychiatric disorders. Volunteers were also excluded if they
were taking oral steroids, tricyclic antidepressants, neurolep-
tics, anticoagulants, digoxin and anti-arrhythmics, or
chronically using anti-inﬂammatories (for example, high
doses of aspirin, ibuprofen) or nutrient supplements. These
criteria were checked with each participant’s primary care
physician. All subjects provided informed written consent
before inclusion in the study, which was approved by the
North of Scotland Research Ethics Committee (NOSREC).
The study was registered at clinicaltrials.gov no.
NCT01245270 and was conducted according to the guidelines
laid down in the Declaration of Helsinki. On both visits, all
anthropometric measurements were made following an over-
night fast.
Study design
In a cross-over design, volunteers (n 8) were randomised and
double-blinded into two groups matched for BMI as well as
age and given a single capsule of either 0·47 g of Mirtoselect®
(a standardised bilberry extract (36 % (w/w) anthocyanins))
which equates to about 50 g of fresh bilberries formulated in
gelatin capsules or a control capsule consisting of microcrystal-
line cellulose in an opaque gelatin capsule, followed by oral glu-
cose tolerance testing (OGTT). The reverse procedure was
conducted following a 2-week washout period. The volunteers
were asked to consume a low-phytochemical diet 3 d before
taking the capsule and for the 24 h after taking the capsule on
both occasions. In addition the volunteers were asked to record
what they ate over the same period in a food diary to ensure that
they adhered to the low-phytochemical diet. Subjects were reim-
bursed travelling expenses on completion of the study.
Oral glucose tolerance testing
In the evening before the test on each visit the volunteers were
asked to consume the same low-phytochemical meal.
Table 1. Baseline characteristics of the lean and overweight diabetic
study volunteers (n 8)
(Mean values and standard deviations)
Mean SD
Age (years) 62·13 4·55
BMI (kg/m2) 30·32 4·38
Height (cm) 174·35 7·37
Body weight (kg) 92·33 15·05
Body weight:height ratio 0·53 0·08
Waist circumference (cm) 105·9 11·44
Hip circumference (cm) 105·1 5·83
Waist:hip circumference ratio 1·01 0·06
Blood pressure (mmHg)
Systolic 142·5 15·70
Diastolic 81·1 7·47
Plasma cholesterol (mmol/l) 4·29 0·91
Plasma glucose (mmol/l) 7·16 1·41
Plasma HDL-cholesterol (mmol/l) 1·18 0·39
Plasma LDL-cholesterol (mmol/l) 2·59 0·87
TAG (pmol/l) 1·42 0·51
NEFA (mmol/l) 0·59 0·14
Fasting plasma insulin (pg/ml) 407·70 208·41
HOMA-IR 3·35 2·19
HOMA-β 405 190
HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeo-
stasis model assessment of β-cell function.
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Volunteers were fasted (10–12 h) overnight before the OGTT.
Venous blood samples were taken through an indwelling can-
nula inserted into a forearm vein at –15, –10 and –5 (fasted)
and at 15, 30, 45, 60, 90, 120, 150 and 300 min after consuming
75 g ofPolycal liquid (carbohydrate, 61·9%; polysaccharide, 49·2
%; sugars, 12·2%; glucose, 0·6%;maltose, 11·6%; http://www.
nutricia.co.uk). Polycal was selected as the main carbohydrate as
it is in the form of polysaccharides and this is closer to normal
dietary consumption than glucose only. It is often used in hospi-
tals as a standard glucose load for OGTT as it is more palatable.
The volunteers consumed the appropriate capsule (0 min), glu-
cose load and a further sample of water (70 ml) within 3 min.
For those volunteers taking the control capsule, additional
sugar (fructose and dextrose/glucose)was added double-blinded
to the water to match the free sugar content of the Mirtoselect®
capsules. Movement during the 300 min OGTT was kept to a
minimum. Plasma glucose concentrations were measured in tri-
plicate using an automated clinical analyser (Kone Oyj). Plasma
insulin was measured in duplicate using an ELISA assay
(Mercodia). The inter- and intra-assay CV were 2·6–3·6 and
2·8–3·4%, respectively. Homeostasis model assessment of insu-
lin resistance (HOMA-IR) was measured using the fasting glu-
cose and insulin values.
Metabolic profile
An automated clinical analyser (Kone Oyj) was used for the
analysis of plasma glucose, TAG, LDL, HDL, NEFA and
cholesterol using commercial kits (Microgenics GmbH).
Mirtoselect®
Mirtoselect® is a standardised hydro-alcoholic extract of
Vaccinium myrtillus L. berries (Mirtoselect®; Indena S.p.A.) con-
taining 36 % (w/w) of anthocyanins by HPLC. The extract is
obtained from frozen ripe fruit of V. myrtillus L. harvested
when ripe during July to September. Predominant anthocyanin
constituents are delphinidin-3-galactoside, delphinidin-3-
glucoside, delphinidin-3-arabinoside, cyanidin-3-galactoside
and cyanidin-3-glucoside (Indena datasheet). Other anthocya-
nins include cyanidin-3-arabinoside, petunidin-3-galactoside,
petunidin-3-glucoside, petunidin-3-arabinoside, peonidin-3-
galactoside, peonidin-3-glucoside, peonidin-3-arabinoside,
malvidin-3-galactoside, malvidin-3-glucoside and malvidin-
3-arabinoside. Mirtoselect® also contains other polyphenols
(phenolic acids, ﬂavonols, proanthocyanidins; about 18 %),
carbohydrates and aliphatic organic alcohols (about 29 %),
fats (about 0·04 %), N compounds (about 1 %), ash (about
0·7 %), with the remaining 15 % undeﬁned. The main sugar
composition of the Mirtoselect® is fructose, 13 %; glucose,
14 %; and sucrose, 4 % (w/w). No side effects of the
Mirtoselect® supplementation were noted. Mirtoselect®
batch no. 29993/M2 was used in the present study.
Plasma ELISA
Plasma was collected in EDTA tubes containing aprotinin
with dipeptidyl peptidase-4 (DPP-IV) inhibitor (Millipore
Ltd) added at 10 µl/ml and stored at –70°C until analysis.
Plasma glucagon, amylin, monocyte chemotactic protein-1
(MCP-1), gastric inhibitory polypeptide (GIP) and insulin
were detected using the commercial Milliplex multiplex
ELISA kit (HMHMAG-34K) according to the manufacturer’s
instructions (Millipore Ltd). All samples were run in duplicate.
The minimum level of detection of glucagon was 6 pg/ml and
the intra- and inter-assay CV were 3 and 7 %, respectively. The
recovery of glucagon added to plasma was approximately
98 %. Similar values for all the other analytes can be found
on the Millipore website (www.millipore.com/).
Glucagon-like peptide-1 RIA
Glucagon-like peptide-1 (GLP-1) concentrations in plasma
were measured by RIA after extraction of plasma with 70 %
ethanol (v/v, ﬁnal concentration). Carboxy-terminal GLP-1
immunoreactivity was determined using antiserum 89390
which has an absolute requirement for the intact amidated
carboxy-terminus of GLP-1 7–36 amide and cross-reacts
less than 0·01 % with carboxy-terminally truncated fragments
and 89 % with GLP-1 9–36 amide, the primary metabolite of
DPP-IV-mediated degradation. The sum of the two com-
ponents (total GLP-1 concentration) reﬂects the rate of
secretion of the L-cell. Sensitivity was below 1 pmol/l, and
intra-assay CV below 5 %(25).
Antioxidant assays
The ferric-reducing activity of plasma (FRAP) assay (Benzie &
Strain(26)) and the Trolox equivalent antioxidant capacity
(TEAC) assay (Dragsted et al.(27)) were used to deﬁne changes
to plasma antioxidant capacity. For the analysis of FRAP in a
microplate format, 6 µl of plasma were added with 18 µl of ster-
ile distilled water and 180 µl of freshly prepared FRAP reagent
(250 mM-sodium acetate (pH 3·6), 1·6 mM-iron (III) chloride
and 0·83 mM-2,4,6-Tris(2-pyridyl)-s-triazine). Samples were
incubated at 37°C for 4 min and absorbance (A593nm; Dynex
Technologies) recorded after 4 min and after a further 30 min
at 37°C. The difference in A593nm between samples and blanks
was calculated and compared with a standard curve of Fe(II)
standard solutions (50–1000 µM). For TEAC analysis a proprie-
tary assay (TEAC Assay; Sigma CS0970) was used and con-
ducted according to the manufacturer’s recommendations.
Brieﬂy, 10 µl of plasma were added to 20 µl of myoglobin
solution and 150 µl of ABTS (2,2’-azino-bis(3-ethylbenzothia-
zoline-6-sulphonic acid)) substrate working solution. Samples
were incubated for 5 min at 21°C (as optimised), the reaction
stopped and the A405nm recorded (Dynex Technologies). The
antioxidant capacity was reported as Trolox equivalents by
referral to the equation obtained from the linear regression of
a Trolox standard curve.
Statistical analysis
AUC was calculated using the trapezoid approximation. For
the incremental version (AUCi), only the extent of interpolated
values above baseline contributed. Values obtained following
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the control and extract capsules were compared by paired t
tests.
Results
The mean body weight of the volunteers remained stable
during the study: 92·3 (SD 15·6) kg on visit 1 compared with
92·3 (SD 15·4) kg on visit 2. The order in which the capsules
were taken (control v. bilberry extract) did not signiﬁcantly
inﬂuence any variable.
Plasma glucose
The ingestion of the bilberry extract lowered the venous
plasma glucose AUCi by 18 % compared with the placebo
(P = 0·003; Fig. 1). All eight volunteers showed a decrease in
plasma glucose AUCi when taking the bilberry extract com-
pared with the placebo (data not shown). The kinetics of gly-
caemia was compared for AUCi for 0–60 min and for 60–300
min but there was no difference between the bilberry extract
and the placebo (Fig. 1(b)). However, the incremental plasma
Fig. 1. (a) Plasma incremental glucose concentrations following consumption of a glucose load with either a single placebo control ( ) or bilberry (Vaccinium myrtillus L.)
extract ( ) capsule. (b) Incremental AUC (AUCi) from 0 to 300 min, 0 to 60 min and 60 to 300 min for plasma glucose concentrations under the control (■) and bilberry
extract ( ) conditions. Values are means for eight subjects, with standard errors represented by vertical bars. Mean value was significantly different from that for the
bilberry extract: *P < 0·05, **P < 0·01.
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glucose concentrations were signiﬁcantly lower at 120, 150 and
180 min after taking the bilberry extract compared with the
placebo control (P = 0·04, 0·02 and 0·004, respectively;
Fig. 1(a)). We also examined the effect of the ingestion of
the bilberry extract on the glycaemic proﬁle(28), deﬁned as
the duration of the incremental postprandial blood glucose
response divided by the blood glucose incremental peak, but
found no effect when compared with the placebo control
(data not shown).
Plasma insulin
The ingestion of the bilberry extract lowered the venous
plasma insulin AUCi by 18 % compared with placebo (P =
0·028; Fig. 2). All but one volunteer showed a decrease in
plasma insulin AUCi when taking the bilberry extract com-
pared with the control (data not shown). There was a 17 %
decrease (P = 0·04) between the extract and placebo control
for the time 60–300 min but not for the early postprandial
phase (0–60 min; Fig. 2(b)). The incremental plasma insulin
Fig. 2. (a) Plasma incremental insulin concentrations following consumption of a glucose load with either a single placebo control ( ) or bilberry (Vaccinium myrtillus L.)
extract ( ) capsule. (b) Incremental AUC (AUCi) from 0 to 300 min, 0 to 60 min and 60 to 300 min for plasma insulin concentrations under the control (■) and bilberry
extract ( ) conditions. Values are means for eight subjects, with standard errors represented by vertical bars. * Mean value was significantly different from that for the
bilberry extract (P < 0·05).
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concentration was also lower at 180 min after taking the bil-
berry extract compared with placebo (P= 0·04; Fig. 2).
Incretin response
The impact of the bilberry extract and the placebo ingestion on
the gut incretin hormones, plasma GIP and GLP-1, secreted
from the intestinal mucosa, as well as glucagon and amylin
secreted from the pancreas was compared at all time points.
There was no difference in treatment for the AUCi for any
of these hormones or for any of the individual time points
compared with placebo (Fig. 3).
Inflammatory and oxidative response
The bilberry extract had no effect on the plasma concen-
trations of the inﬂammatory adipokine MCP-1 (Fig. 4(a)) com-
pared with the placebo control at any of the time points
studied. Similarly there was no effect of the bilberry extract
on the oxidative state measured by plasma FRAP (Fig. 4(b))
and TEAC (Fig. 4(c)), compared with placebo.
Discussion
The present study shows that the ingestion of a capsule con-
taining concentrated bilberry extract gives a reduced
postprandial glycaemic response in volunteers with T2D con-
trolled by diet and lifestyle alone compared with an inert pla-
cebo capsule. Given that the glucose concentrations between
the volunteers taking the bilberry and control extract are differ-
ent during the later time points (120, 150 and 180 min) it
might be suggested that the active ingredient takes some
time before it has an effect, perhaps due to digestion or
where it is having its effect, for example, time to reach the gas-
trointestinal tract. This differs from previous studies in nor-
mal/healthy volunteers where the decrease in the plasma
glucose between the volunteers taking the berries and control
extract occurs at the earlier time points(23,29,30). This may be
due to differences in glucose metabolism in volunteers with
T2D or differences between the studies, for example, the
ingestion of a capsule may take longer to reach the gastrointes-
tinal tract compared with a berry purée. The bilberry extract
also decreased plasma insulin compared with the control in
a proﬁle that mirrors the postprandial glycaemic response.
One explanation is that the decreased plasma insulin is a result
of the lower plasma glucose or the volunteers become more
insulin sensitive.
One study in normal/healthy volunteers that reported a
mean decrease in plasma glucose after 15 and 30 min follow-
ing the consumption of a commercial apple juice also observed
parallel changes in the plasma concentrations of the incretins,
GLP-1 and GIP(29). Both these incretins are produced in the
Fig. 3. Plasma incremental concentrations of (a) gastric inhibitory polypeptide (GIP), (b) glucagon-like peptide-1 (GLP-1), (c) glucagon and (d) amylin from 0 to 300
min following consumption of a glucose load with either a single placebo control ( ) or bilberry (Vaccinium myrtillus L.) extract ( ) capsule. Values are means for eight
subjects, with standard errors represented by vertical bars.
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intestinal mucosa and are normally secreted when food is eaten
in order to reduce glycaemic excursion by causing an increase
in insulin secretion. However, GLP-1 also has other effects
such as inhibiting glucagon secretion from the pancreas and
by decreasing the time it takes for food to empty from the
stomach. In the present study we did not ﬁnd an effect of
the bilberry extract on GIP, GLP-1 or glucagon. Further, we
also looked at the effect of the bilberry extract on the pancrea-
tic hormone amylin which also affects plasma glucose concen-
tration independent of insulin secretion. Again, we did not
observe any effects of the bilberry extract on plasma amylin
compared with the placebo.
Bilberries are rich in anthocyanins, recognised for their abil-
ity to provide and activate cellular antioxidant protection, inhi-
bit inﬂammatory gene expression, and consequently protect
against oxidant-induced and inﬂammatory cell damage and
cytotoxicity(2–4). In light of this we investigated the effects of
a bilberry extract on the inﬂammatory marker MCP-1 that
plays a role in the recruitment of monocytes due to the low-
grade inﬂammation associated with obesity(31). However, in
the present study we did not see any changes in plasma levels
of MCP-1 due to the ingestion of the bilberry extract com-
pared with the control. Similarly, we could not detect any
alterations in plasma TEAC or FRAP, both markers of oxi-
dation. It may well be that any effects of the bilberry extract
on markers of inﬂammation and oxidation take longer than
5 h to occur. In addition, our sample size of eight volunteers
was modest, and meant that we had 80 % power to detect
treatment effects about 1.5 times the natural within-individual
variability (SD) in outcome measurements. Therefore any nega-
tive results reported need to be viewed in this context.
It has been suggested that berry polyphenols inhibit
α-glycosidase, the enzyme responsible for the digestion of
sucrose to glucose in the intestinal epithelium. Two anthocya-
nins (cyanidin-3-rutinoside(32) and cyanidin-3-galactoside(33,34))
have been shown in vitro to be inhibitors of α-glucosidase.
Cyanidin-3-galactoside is present in bilberries(35) and cranber-
ries(24), and has shown a synergistic effect with acarbose(34).
Acarbose is used as an inhibitor of α-glucosidase in the treat-
ment of diabetes. Also proanthocyanidins have shown potent
α-glucosidase inhibitory activity(36,37). The anthocyanins in the
bilberry extract are well documented(38,39) and include both
cyanidin-3-galactoside and proanthocyanidins. As the glucose
load Polycal used here for the OGTT is composed of complex
carbohydrates, the reduced postprandial glycaemia in response
to the ingestion of the bilberry extract may be due in part to a
reduction in the breakdown of carbohydrates.
In addition there is evidence that polyphenols can affect the
absorption of glucose across the intestine. This is thought to
be mediated by active Na-dependent transport via Na glucose
co-transporter 1 (SGLT1) and facilitated Na-independent trans-
port via GLUT2(40). The Na+-dependent SGLT1-mediated
Fig. 4. Plasma concentrations for (a) monocyte chemotactic protein-1 (MCP-1), (b) ferric-reducing ability of plasma (FRAP) and (c) Trolox equivalent antioxidant
capacity (TEAC) from 0 to 300 min following consumption of a glucose load with either a single placebo control ( ) or bilberry (Vaccinium myrtillus L.) extract ( )
capsule. Values are means for eight subjects, with standard errors represented by vertical bars.
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glucose uptake appears to be inhibited by several phenolic acids
(for example, chlorogenic, ferulic and caffeic acids)(13) as well as
by glucosides of quercetin(20). The glucose transport by GLUT2
was inhibited by the ﬂavonols quercetin and myricetin(19,21).
These phenolic acids and ﬂavonols with inhibitory activity
against intestinal glucose uptake are common polyphenolic con-
stituents of berries(41–43). Thus, both a reduced breakdown of
carbohydrates and lowered intestinal absorption may contribute
to the improved glycaemic excursion. Further studies are needed
to determine which of these mechanisms are more important in
vivo. For example, comparison of the bilberry extract responses
to Polycal v. a glucose OGTT would resolve how important
to the breakdown of carbohydrates is in the action of the bilberry
extract. Although dietary ﬁbre has been shown to affect post-
prandial glucose(44), the bilberry extract used only contains 18
mg of dietary ﬁbre (15 mg in soluble form). This small quantity
is unlikely to explain the reduced glycaemic response. Future
studies would also focus on dose–response effects to support
the observed changes in postprandial glucose in volunteers
with and without T2D.
In addition to berries, other foods rich in polyphenols have
been implicated in modifying glycaemic response. Various
studies on the effect of coffee have suggested that the chloro-
genic acid in coffee might have an antagonistic effect on the
transport of sucrose(45) and attenuate the glycaemic response
to sucrose(46). However, as far as we know, none of these studies
has shown a change in the AUCi values for glucose or insulin in
response to the polyphenols compared with the control.
In conclusion, to our knowledge this is the ﬁrst report show-
ing that ingestion of a concentrated bilberry extract at amounts
that can be easily tolerated produces a reduced AUCi postpran-
dial glycaemia and insulinaemia in volunteers with T2D. The
probable mechanism(s) for the reduced glycaemic response
are reduced rates of carbohydrate digestion and/or absorption.
The use of berry polyphenols as phytochemicals capable of low-
ering the glycaemia response to carbohydrates not only in sub-
jects with diabetes but also in those with impaired glucose
tolerance control may prove to be useful in helping control
blood sugar. Such a strategy could complement the effectiveness
of other lifestyle interventions such as avoidance of overweight
and the need to take regular exercise.
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